Ratio Therapeutics

Ratio Therapeutics’ Trillium targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets.  

Pharmaceutical

$20M

Latest Funding

Series A

Latest Funding Stage

2023-02-01

Funding Date

18

Employees

United States

Location

Boston, Massachusetts

City & State

Key Contacts
Unlock Contact Information

Upgrade to access founder details

Upgrade Now
Open Positions
View Careers Page
Hiring For
n/a
Unlock Tech Stack Data

Upgrade to access technology insights

Upgrade Now

Similar Startups

EvidenceHunt
EvidenceHunt Logo

EvidenceHunt is an AI-powered research assistant developed by medical professionals for healthcare research. Our focus is on delivering tools that streamline gathering and analyzing clinical evidence. With features like AI Chat for interactive queries and comprehensive Direct Search options, EvidenceHunt allows precise data retrieval andanalysis.

Ignota Labs
Ignota Labs Logo

Ignota Labs recognizes that safety errors during the drug discovery process can result in expensive setbacks and delays in bringing life-changing medications to market. Ignota Labs world leading AI methods, which include deep learning and machine learning approaches, are intended to examine complicated molecular data and provide accurate toxicitypredictions.

Monument Therapeutics
Monument Therapeutics Logo

Monument Therapeutics medical approach utilizes proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, enabling researchers to focus on the advancement of neuroscience drugs in areas of unmet medical needs.

Stablepharma
Stablepharma Logo

Stablepharma’s technology platform, StablevaX™ converts existing approved vaccines, therapeutics and diagnostics into fridge free thermostable products that do not require refrigeration to preserve them, thereby addressing the global challenges of the cold chain. Stablepharma’s R&D team have identified up to 60 vaccine candidates that could be suitable for StablevaX™ technology.